Inventor
BABB ROBERT
US27 patents
⚠️ This page may combine multiple inventors who share the name “BABB ROBERT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
26 patentsUS10787501B1Sep 29, 2020
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA224 citations98
US7771997B2Aug 10, 2010
Enhanced expression and stability regions
REGENERON PHARMA55 citations98
US10975139B1Apr 13, 2021
Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA15 citations93
US10954289B1Mar 23, 2021
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA28 citations93
US10752698B2Aug 25, 2020
Method for generating high affinity antibodies
REGENERON PHARMA5 citations84
US9222106B2Dec 29, 2015
Enhanced expression and stability regions
REGENERON PHARMA4 citations84
US11142578B2Oct 12, 2021
Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
REGENERON PHARMA6 citations83
US11808766B2Nov 7, 2023
Method for generating high affinity antibodies
REGENERON PHARMA2 citations73
US11530277B2Dec 20, 2022
Compositions and methods for making antibodies based on use of an expression-enhancing locus
REGENERON PHARMA2 citations73
US11732030B2Aug 22, 2023
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA2 citations72
US11787867B2Oct 17, 2023
Anti-GITR antibodies and uses thereof
REGENERON PHARMA2 citations71
US9562238B2Feb 7, 2017
Enhanced expression and stability regions
REGENERON PHARMA1 citations63
US12577304B2Mar 17, 2026
Anti-CD3 antibodies with low binding affinity
REGENERON PHARMA0 citations62
US12545735B2Feb 10, 2026
Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
REGENERON PHARMA0 citations62
US12528883B2Jan 20, 2026
Compositions and methods for making antibodies based on use of expression-enhancing loci
REGENERON PHARMA0 citations62
US12503520B2Dec 23, 2025
Compositions and methods for making antibodies based on use of an expression-enhancing locus
REGENERON PHARMA0 citations62
US12480947B2Nov 25, 2025
Method for generating high affinity antibodies
REGENERON PHARMA0 citations62
US12251440B2Mar 18, 2025
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
REGENERON PHARMA0 citations62
US11512144B2Nov 29, 2022
Compositions and methods for making antibodies based on use of an expression-enhancing loci
REGENERON PHARMA0 citations62
US12331127B2Jun 17, 2025
Therapeutic uses of anti-GITR antibodies
REGENERON PHARMA0 citations60
US12466870B2Nov 11, 2025
NY-ESO-1 T cell receptors and methods of use thereof
REGENERON PHARMA0 citations57
US12371487B2Jul 29, 2025
Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
REGENERON PHARMA0 citations56
US11111314B2Sep 7, 2021
Non-human animals that select for light chain variable regions that bind antigen
REGENERON PHARMA0 citations52
US10415055B2Sep 17, 2019
Enhanced expression and stability regions
REGENERON PHARMA0 citations52
US9932605B2Apr 3, 2018
Enhanced expression and stability regions
REGENERON PHARMA0 citations52
US10787522B2Sep 29, 2020
VL antigen binding proteins exhibiting distinct binding characteristics
REGENERON PHARMA0 citations41